CD274 and neoplasm: showed that IL-15 super-agonist N-803 plus anti-PD-L1 mAb could reduce MC38-CEA (colon cancer cell) tumor burden and increased survival rate as compared to N-803 and anti-PD-L1 monotherapies in MC38-CEA colon tumor-bearing mice (115).